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Abstract: Statins form the cornerstone of pharmaceutical cardiovascular disease prevention. 
However, despite very effective statin intervention, the majority of events remain unpreventable. 
In some cases statin therapy alone is insufficient to achieve adequate lipid levels whereas other 
patients are unable to tolerate statins. This calls for additional treatment options. Niacin has a 
long history of success in reducing low-density lipoprotein cholesterol and triglycerides, and 
increasing high-density lipoprotein cholesterol. It was the first lipid-lowering drug to demonstrate 
a reduction in cardiovascular events, and remains the only one that has consistently shown 
benefits on surrogate outcomes when added to background therapies of other lipid-lowering 
drugs, including statins. Niacin’s uptake in clinical practice has been less successful due to its 
side-effect profile, most notable being flushing. The uncovering of the mechanism by which 
flushing is induced, together with the development of a prostaglandin D2 receptor inhibitor 
(laropiprant) which reduces this downstream flushing effect of niacin, has sparked new promise 
in therapeutic lipid management. It provides an additional treatment option into managing lipid 
abnormalities. The uptake in clinical practice of the niacin–laropiprant combination will depend 
on the relative improvements experienced by the patient in the side-effect profile compared to 
other treatment options, as well as on the the keenly-awaited outcome studies currently underway. 
Until these data become available guidelines and recommendations are unlikely to change and 
niacin’s position in therapeutic cardiovascular risk prevention will be determined by clinician 
opinion and experience, and patient preferences.
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Introduction
Cardiovascular disease (CVD) is the leading cause of illness and death in the world 
and this statistic is not projected to change in the next decade.1,2 It manifests most 
frequently as ischemic heart disease and cerebrovascular disease, and atherosclerosis 
is the primary cause of this.3 Research into understanding the underlying mechanisms 
of disease together with the formulation of compounds that are able address the 
underlying pathology has now spanned numerous decades. The fact that athero-
sclerotic plaque is largely made up of cholesterol has been known since the middle 
of the 19th century and, since then, abundant data link hypercholesterolemia to 
atherogenesis.4 The most extensively researched of the pharmaceutically modifiable 
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risk factors is cholesterol; in particular, the lowering of 
low-density lipoprotein cholesterol (LDL-C) forms the 
primary target of focus in CVD risk prevention.5,6 Statins 
form the cornerstone of pharmaceutical CVD prevention, 
and their efficacy in reducing mortality in both primary and 
secondary prevention settings is beyond dispute.7,8 Over the 
past decade these drugs have been particularly successful 
in the market, growing in excess of $25 billion.9 However 
despite very effective statin intervention the majority of 
events remain unpreventable. Around 20% of patients in 
the statin arm of the Heart Protection Study suffered from 
major cardiovascular events in 5 years, and it is reckoned 
that only 40%–50% of potential events may be prevented by 
statin therapy.10,11 Furthermore, statin therapy suffers from 
several limitations.4 These include both lack of sufficient 
efficacy and clinical side-effects related to their use. The 
treatment of 1000 patients is likely to prevent 37 events at 
the cost of five discontinuations due to side effects.12 The 
main disadvantage of statins is their shallow dose efficacy 
profile in that doubling the dose only results in a 5%–7% 
extra reduction in LDL-C,13,14 but this occurs with an 
exponential effect in increasing side effects.15 This provides 
the drive in the search for additional benefits beyond statin 
treatment.
Low-density lipoprotein  
cholesterol and statins
LDL is the main atherogenic lipoprotein particle and remains 
the primary target for lipid-lowering therapy.5,6 Early epi-
demiological studies incriminated high levels of LDL-C as 
being atherogenic with the serum total cholesterol (TC) as 
a good correlate for LDL-C levels.5 This was followed by 
unequivocally demonstrating the clinical benefit of LDL-C 
lowering. The most notable evidence comes from the clinical 
trials of statins.7,8 Their primary effect on the lipid parameters 
is their ability to lower LDL-C. Statins act by inhibiting the 
enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG 
CoA) reductase, which catalyzes the rate-limiting step in 
cholesterol synthesis. Inhibition of HMG CoA reductase leads 
to increased expression of LDL receptors on hepatocytes 
with increased LDL-C uptake from the circulation. Despite 
being prescribed for their cholesterol-lowering effect, statins 
have several other advantageous pleiotropic effects counter-
ing atherosclerosis. The pleiotropic effects of statins include 
improvement of endothelial dysfunction, increased nitric 
oxide bioavailability, antioxidant properties, inhibition of 
inflammatory responses, and stabilization of atherosclerotic 
plaques.10
Despite their success and the substantial benefits 
attributable to statins a significant preventable gap remains. 
There is also increasing demand for LDL-C reductions 
of more than 50%, and approaching 90% in some cases 
of familial hypercholesterolemia, and as LDL-C targets 
are progressively reduced in patients with established 
coronary heart disease. Statins also show wide variation in 
dose response,15 variations in bioavailability, and no clear 
pharmacogenetic basis to efficacy or safety.16,17
Apart from the benefits shown following statin treatment, 
lowering of LDL-C seems beneficial irrespective of the 
method employed.18 A meta-analysis of five diet, three bile 
acid sequestrant, one surgery, and 10 statin trials, with 81,859 
participants, showed a relationship between LDL-C lowering 
and reduction in cardiovascular events.19 Professional 
guidelines therefore focus primarily on LDL-C.5,6,20 However, 
demonstration of a mortality benefit is still awaited for most 
other therapies which lower LDL-C concentrations.
Owing to the disease burden and the substantial residual 
risk which remains despite statin treatment, the need exists 
for additional therapies. This may in part be due to the 
success of statin treatment, where newer agents have to show 
equivalent efficacy or additional benefit on the background of 
statin treatment, which is proving very costly in the clinical 
trial setting.21
Niacin
Vitamin B3 is essential to all living cells. There are two forms 
of vitamin B3: nicotinic acid (or niacin) and nicotinamide. 
Both the acid and the amide are precursors to the coenzyme, 
nicotinamide adenine dinucleotide (NAD+) and its 
phosphorylated form NADP, which are key factors in 
dehydrogenation reactions.22 These molecules are also 
essential components of numerous biosynthetic pathways, 
cell protection, and signaling mechanisms.23,24 Vitamin 
B3 was initially best known for its clinical manifestation 
as a deficiency. Deficiency of vitamin B3 was referred to as 
the disease with the four ‘D’s’: namely: dermatitis, diarrhea, 
dementia and death.25 Two centuries after pellagra was first 
described in 1735, its etiology was elucidated. It was shown 
that nicotinic acid could cure black tongue in dogs, which 
was an early animal model for pellagra.26
It was a further two decades later, in the early 1950s 
that the lipid-lowering effects of niacin were described by 
the pathologist Rudolf Altschul.27 He reported his initial 
findings following experiments in rabbits and then in a 
landmark study of its effects in humans.28 Niacin was the 
first medication to show notable lipid-lowering effects in Drug, Healthcare and Patient Safety 2010:2 63
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humans. Merely a year after Altschul’s report it was shown 
by another group that 3 g of nicotinic acid per day was able 
to reduce plasma cholesterol by 16% on average in a group 
of patients with familial hypercholesterolemia.29 Importantly, 
this study showed that the reduction in cholesterol was due to 
a decrease in β-lipoproteins, ie, LDL-C. Furthermore, it was 
also shown that the ratio of β to α1-cholesterol [ie, LDL-C 
to high-density lipoprotein cholesterol (HDL-C)] decreased 
from 9.0 to 5.6.
Clinical studies with niacin
These initial findings formed the basis for investigating the 
effect of lipid lowering to reduce cardiovascular events. 
Table 1 depicts the most notable clinical trials involving niacin. 
Niacin was the first lipid-lowering agent shown to significantly 
reduce cardiovascular events, although not in-trial mortal-
ity, in the Coronary Drug Project (CDP) which randomized 
3908 men with previous myocardial infarction (MI) to either 
nicotinic acid or placebo.30 Major coronary heart disease 
(CHD) events, nonfatal MI, and cerebrovascular events were 
reduced by 22% but there was no effect on overall mortality. 
However in the 15-year post-trial follow-up, nearly 9 years 
after termination of the trial, mortality from all causes was 
11% lower in the nicotinic acid group.31 The other arms of 
the CDP using clofibrate, d-thyroxine, and estrogen showed 
no effect or were terminated early.
Several long-term clinical studies with nicotinic acid 
have demonstrated a reduction in surrogate outcomes, 
CHD events, and mortality, when used in combination 
with other lipid-modifying drugs which include colestipol 
(a bile acid sequestrant),32 clofibrate33 and statins.34,35 The 
Cholesterol-Lowering Atherosclerosis Study (CLAS)32 was 
a randomized, placebo-controlled, angiographic trial testing 
combined colestipol hydrochloride and niacin therapy in 162 
men aged 40 to 59 years with previous coronary bypass sur-
gery. Atherosclerosis regression, as indicated by perceptible 
improvement in overall coronary status, occurred in 16.2% 
of colestipol–niacin treated men vs 2.4% placebo treated 
(P = 0.002). In the underpowered Stockholm Ischemic Heart 
Disease Secondary Prevention Study, 555 patients received 
either clofibrate and nicotinic acid, or standard treatment.33 
Total mortality was 82 cases in the control group and 61 
Table 1 Notable trials including niacin30,32–36,39,40
Study Year reported Interventions Number patients Outcome measures Note
CDP 1975 Niacin  
Clofibrate  
Thyroxine  
estrogen
8341 Decreased nonfatal  
Mi for Niacin arm
1119 patients  
received niacin;  
all other arms had  
no effect or were  
terminated early
CLAS 1987 Niacin and  
colestipol
162 Coronary angiography Decreased  
atherosclerosis
S-iHD Niacin and clofibrate vs  
standard care
555 Overall mortality Not blinded  
No placebo control 
Underpowered
HATS 2001 Niacin and simvastatin vs  
Antioxidants vs niacin and  
Simvastatin and antioxidants  
vs Placebo
160 Coronary angiography  
and MACe
reduction in MACe  
on niacin and  
simvastatin arm
ArBiTer 2 2004 Niacin vs placebo  
Added to statin
160 ciMT ciMT progression 
between groups was  
not statistically  
significant
ArBiTer 6 2009 Niacin vs ezetimibe  
Added to statin
208 ciMT Superior efficacy of 
Niacin over ezetimibe
AiM HiGH Due to report  
in 1–2 years
Niacin vs placebo  
Added to statin
∼3300 MACe
HPS2 – THriVe 
 
Due to report  
in 4–5 years 
Niacin and laropiprant vs  
placebo Added to  
simvastatin ± ezetimibe
∼28 000 
 
MACe 
 
 
 
Abbreviations: CDP, Coronary Drug Project; CLAS, Cholesterol-Lowering Atherosclerosis Study; S-iHD, Stockholm ischemic Heart Disease Secondary Prevention Study; 
HATS, HDL-Atherosclerosis Treatment Study; ArBiTer, Arterial Biology for the investigation of the Treatment effects of reducing Cholesterol; AiM-HiGH, HPS2 – THriVe, 
Heart Protection Study 2-Treatment of HDL to reduce the incidence of Vascular events; ciMT, carotid intima media thickness; MACe, major adverse cardiovascular event.Drug, Healthcare and Patient Safety 2010:2 64
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in the treatment group, a 26% reduction (P  0.05). The 
main limitation of this study is that it was not blinded and 
was without a placebo control. The Arterial Biology for 
the Investigation of the Treatment Effects of Reducing 
Cholesterol (ARBITER) 2 study investigated the effect 
of niacin added to background statin treatment in patients 
with known CHD.34 This was a double-blind randomized 
placebo-controlled study involving 167 patients, and the 
primary endpoint was the change in common carotid 
intima-media thickness (cIMT) after 1 year. The overall 
difference in cIMT progression between the niacin and 
placebo groups was not statistically significant (P = 0.08). 
The HDL-Atherosclerosis Treatment Study (HATS) enrolled 
160 patients who were randomly assigned to receive one of 
four regimens: simvastatin plus niacin, antioxidants, simv-
astatin-niacin plus antioxidants, or placebos. The primary 
end point was arteriographic evidence of a change in luminal 
coronary stenosis and the secondary occurrence of a first 
cardiovascular event.35 The study showed no effect of anti-
oxidants but proved that patients receiving simvastatin in 
combination with niacin had a significant reduction in car-
diovascular events but a lesser increment in HDL-C. The 
recently-reported ARBITER 6 study compared niacin to 
ezetimibe in patients who were receiving baseline statin 
treatment.36 The primary endpoint was the between-group 
difference in the change from baseline in the mean cIMT 
after 14 months. The trial was terminated early, on the basis 
of efficacy, according to a prespecified analysis conducted 
after 208 patients had completed the trial. As compared with 
ezetimibe, niacin had greater efficacy regarding the change 
in mean cIMT over 14 months (P = 0.003).
These studies either did not test the additional benefit of 
niacin over statin treatment or when this was attempted, such 
as in the ARBITER studies, the surrogate marker of cIMT 
was employed. Furthermore, the limitations of employing 
surrogate markers need to be appreciated.37 The use of the 
cIMTs as a surrogate marker for coronary atherosclerosis 
remains controversial. Although in observational studies 
the cIMT has been shown to predict future cardiovascular 
events, it is sometimes less clear what the changes in mea-
surements under certain circumstances truly imply.37 There 
are therapies other than niacin that retard the progression of 
cIMT (ie, estrogen and thiazolidinediones) but do not reduce 
the incidence of cardiovascular events.37,38
These uncertainties call for outcome studies which 
will unequivocally demonstrate the benefit of niacin in 
addition to statin treatment. Fortunately, such studies are 
currently underway. The first is the Heart Protection Study 
2-Treatment of HDL to Reduce the Incidence of Vascular 
Events (HPS2-THRIVE) which will evaluate niacin plus 
laropiprant compared to placebo in patients with established 
cardiovascular disease on a background of simvastatin 
40 milligrams (mg) with or without ezetimibe.39 This study 
is currently still recruiting patients and aims to include 
around 28,000 individuals with a prespecified subgroup of 
6000 patients with diabetes. The findings are expected to 
be reported in 4–5 years’ time. The other outcome study 
underway is the Atherothrombosis Intervention in Metabolic 
syndrome with low HDL-C⁄high triglyceride and Impact on 
Global Health outcomes (AIM-HIGH) which compares a 
modified-release niacin in patients with established coronary 
heart disease allied with dyslipidemia to placebo in patients 
already receiving simvastatin.40 This study is to include 
around 3300 patients and it is hoped that it will be reported 
in the next year. These studies will also help in casting more 
light on the other lipid parameters (other than LDL-C) on 
which niacin also has an effect.
effect of niacin and position  
in treatment of lipid abnormalities
Whereas the vitamin activity of niacin, which involves cellular 
processes, is apparent in milligram doses, the lipid-modifying 
effects are seen in doses a thousand-fold greater. Owing to 
its favorable effects not only on LDL-C but also on HDL-C 
and triglycerides (TG), niacin has been referred to as the 
‘broad-spectrum’ lipid drug.41 The magnitude of these effects 
can be broadly summarized by the ‘rule of 20’, namely a 20% 
reduction in LDL-C and TG, and a 20% increase in HDL-C, 
at a dose of more than 1.5 g/day.41,42
Lipoproteins are complex particles and can be referred 
to as being heterogeneous and polydisperse.43 Heterogeneity 
refers to the presence of several different subparticle classes 
within the lipoproteins. For example, depending on the 
analytical technique used, as many as 14 subfractions of 
high-density lipoprotein (HDL) can be distinguished. The term 
polydisperse indicates that each of the subclasses includes 
varying proportions of lipids and proteins. Around 60 protein 
types are associated with HDL and about 12 with LDL.44,45
Low density lipoprotein
Niacin is a potential treatment option to lower LDL-C. 
This could include patients on existing statin therapy where 
additional reduction is desired, such as patients with familial 
hypercholesterolemia, or in patients’ intolerant to statin 
treatment. Not only does niacin lower LDL-C but it also has 
a potential further beneficial effect on LDL. Like fibrates, Drug, Healthcare and Patient Safety 2010:2 65
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it shifts the subtype distribution by reducing the number 
of smaller and denser particles to ones which contain more 
cholesterol.46 Large numbers of studies including the Quebec 
Cardiovascular study have confirmed the association of small 
dense LDL with cardiovascular disease, which reported that 
men with small dense LDL particles had an increased risk of 
CAD compared with men with normal-sized LDL particles, 
independent of LDL-C, triglyceride, and the total cholesterol: 
HDL-C ratio.47,48 The beneficial effects of niacin may be 
underestimated if LDL-C is the only parameter being assessed. 
This potential beneficial effect of niacin is tantalizing, as no 
prospective studies have specifically examined whether alter-
ing particle size profiles results in benefits on cardiovascular 
events, though analysis of the Veterans Affairs High-Density 
Lipoprotein Intervention Trial (VA-HIT) study does suggest 
some role for this mechanism, admittedly without including 
non-HDL-C or apolipoprotein B in the model.49
High-density lipoprotein
Analogous to LDL, the HDL class also comprises a hetero-
geneous population of particles. The inverse relationship 
between HDL-C levels and atherosclerotic CVD provides 
the epidemiological basis for the widely accepted hypothesis 
that HDL-C is atheroprotective.50,51 Experimental studies, 
which include limited work on humans, have shown that 
HDL has several distinct but potentially overlapping athero-
protective functions. These include the well-known reverse 
cholesterol transport52 as well as reductions in oxidative stress 
and innate immune inflammation.53 More HDL-associated 
proteins are involved in immune/inflammatory functions 
than in lipid transport and metabolism, suggesting the 
fundamental role for HDL in innate immunity.44 Niacin is 
the most powerful drug currently available to raise HDL-C. 
Following the epidemiological evidence on HDL-C it would 
be intuitively reasonable to attempt to raise HDL-C with the 
expectation of reducing cardiovascular events. However, as 
opposed to LDL-C lowering, therapies to intervene in order 
to raise HDL-C have proven to be ‘not that simple’. Some 
HDL therapies may reduce CVD without actually chang-
ing HDL-C concentrations.54 The intravascular ultrasound 
study (IVUS) of the effects of five weekly infusions of a 
hyper-functional apolipoprotein A-1-Milano (apoA-1) Milano, 
produced significant regression of coronary atherosclerosis 
after three months. In contrast in the Investigation of Lipid 
Level Management to Understand Its Impact in Athero-
sclerotic Events (ILLUMINATE) trial which investigated 
the cholesterol ester transfer protein (CETP) inhibitor, 
torcetrapib in 15,000 patients, HDL-C increased by 72% and 
LDL-C decreased by 25%, but this trial was terminated early 
because the treatment arm had an increase of major cardio-
vascular events by 25%, and death from cardiovascular causes 
by 40%.55 The outcome studies with niacin that are currently 
underway will also help answer the question on raising HDL. 
Analogous to the apparent improvement in the LDL profile, 
niacin also causes a shift in the HDL profile leading to more 
HDL2 (larger, cholesterol-rich particles) than HDL3 (small, 
lipid-poor particles).41 Whether this shift is beneficial, as is 
sometimes advocated, is not clear. In general, controversy still 
exists in regard to whether the anti-atherogenic effect of HDL 
can be attributed to one or both HDL subfractions, and what 
is the relative importance of HDL2 and HDL3 cholesterol.56 
In the Kuopio Study57 and Quebec City Suburbs Study,58 
HDL2 was inversely associated with CHD, whereas HDL3 had 
a stronger inverse association with CHD in the Physician’s 
Health Study59 and the 9-year follow-up of the Caerphilly 
study.56,60 These differences in the results of various studies 
may be attributable to the different assay methods used, to 
ethnic variations, or to the probable heterogeneity of the sub-
fractions with different physiological functions.56
Triglycerides
Niacin generally reduces triglyceride levels by 15% to 25% 
in a dose-dependent manner, with the triglyceride-reduction 
effects seeming to parallel its action in raising HDL-C.41,61,62 
It is well-established that elevated serum TG levels are 
associated with increased risk for atherosclerotic events.63 
However to prove its causality is more difficult, and 
directly targeting TG in curbing cardiovascular disease 
is more controversial.62,64 As high serum TG levels tend 
to ‘keep bad company’, being associated with abnormal 
lipoprotein metabolism, as well as with other cardiovascular 
risk factors including obesity, insulin resistance, diabetes 
mellitus, and lowered levels of HDL-C, it becomes more dif-
ficult to distinguish between cause and effect. Some causes of 
hypertriglyceridemia have no apparent effect on atherosclerotic 
vascular disease, making it difficult to prove that elevated TGs 
are a risk factor, as opposed to being an innocent bystander.62,65 
Despite no clear consensus on the benefits of directly 
targeting hypertriglyceridemia to reduce CVD, it is generally 
recommended to reduce significantly-elevated triglyceride 
concentrations in order to reduce the risk of pancreatitis.66,67
Lp(a) lipoprotein
Lp(a) lipoprotein is a lipoprotein of unknown physiologic 
function that is composed of apolipoprotein B-100 to which 
apolipoprotein(a) is covalently bound.68 Elevated plasma Drug, Healthcare and Patient Safety 2010:2 66
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Lp(a) lipoprotein concentrations are associated with CHD.69 
A key unresolved question is whether an elevated plasma 
level is the cause or the consequence of CAD, but recent 
epidemiological and genetic data suggest the hypothesis 
that lowering the plasma Lp(a) lipoprotein concentration 
by pharmacological means may lower the risk of CAD.70–72 
These recent findings have generated renewed interest in 
this molecule as a potential therapeutic target. The only cur-
rently approved agent to effectively lower Lp(a) lipoprotein 
levels is niacin. Other drugs in development (including 
anacetrapib-a CETP inhibitor, mipomersen – an antisense 
oligonucleotide directed against apolipoprotein B-100 and 
thyroid analogues) are also able to significantly reduce Lp(a) 
lipoprotein levels.
Position of niacin in treating 
hypercholesterolemia
From this it is clear that niacin has an advantageous effect 
on most lipid parameters. As statins form the mainstay of 
CVD risk prevention, other treatment options are gener-
ally only considered as add-on treatment to statins. Only in 
cases where patients are either intolerant to statins, or when 
statins are contraindicated, or in cases where the primary 
abnormality is that of hypertriglyceridemia, nonstatin treat-
ments are considered as first line treatments.5,73 In cases 
where statins are not considered as the front line treatment, 
there is no clear guidance which drug is the best alternative, 
nor is there clear guidance on which treatment should follow 
statin treatment. Currently the only other treatment options 
include: fibrates, bile acid sequestrants and ezetimibe. As is 
the case with niacin, none of these therapies have outcome 
data when combined with statins.5,6
Mechanism of action
The mechanism by which niacin affects plasma lipids is not 
completely understood.73,74 The basic mechanism for the 
lipid-modifying effects of nicotinic acid has previously been 
attributed to its inhibition of lipolysis in adipose tissue.75 
The reduction in free fatty acids liberated from adipose tis-
sue results in a reduction of hepatic triglycerides available 
for very low density lipoprotein and LDL synthesis. More 
than 40 years ago Carlson described how nicotinic acid is 
rapidly taken up and preferentially accumulates in the adipose 
tissue.76 This mechanism was supported by the discovery 
of a specific high-affinity receptor on the membranes of 
adipocytes.77 This is a G-protein coupled receptor known 
as GPR109A but later specific GPR109A agonist showed 
no effects on lipids. This is only one of the potential 
mechanisms by which nicotinic acid may affect lipids, 
and it is now believed that physiologically and clinically, 
this pathway may be only a minor factor in explaining 
the lipid effects of niacin.78 New findings indicate that 
niacin directly and noncompetitively inhibits hepatocyte 
diacylglycerol acyltransferase-2 (DGAT-2), a key enzyme 
for TG synthesis. The inhibition of TG synthesis by niacin 
results in accelerated intracellular hepatic apolipoprotein 
B degradation and the decreased secretion of VLDL and 
LDL particles.78 Niacin also retards the hepatic catabolism 
of apolipoprotein A-I which explains the increases in HDL 
half-life and concentrations of lipoprotein A-I HDL subfrac-
tions, which augment reverse cholesterol transport.78
Safety and side effects of niacin
Despite its ability to significantly improve all these lipid 
parameters, relatively few clinicians resort to niacin 
as a treatment option. Apart from lacking evidence in 
demonstrating a benefit on all cause mortality its use is 
also hampered by its side-effect profile. One in depth report 
on the discontinuation of lipid-modifying drugs in clinical 
practice gauged the one-year adjusted cumulative incidence 
of discontinuation for extended-release (ER) niacin to be 
55.4%.79 This may not sound that encouraging, but the 
same study also found the adjusted cumulative incidence 
of discontinuation was 28.9% in statin users. The most 
notable side-effect leading to discontinuation of niacin is 
flushing. This side effect, although harmless, strongly affects 
patient compliance. Nicotinic acid was initially used as plain 
nicotinic acid, in crystalline immediate release form. In an 
attempt to minimize flushing, various release formulations 
were developed. Initially, a sustained release formulation 
was developed but this was associated with hepatotoxicity 
and its clinical use was abandoned. A prolonged release 
formulation, known as ER niacin (marketed as Niaspan) 
was developed. This compound has absorption rates between 
plain nicotinic acid and sustained release forms, while 
having equivalent efficacy to alter lipid parameters.80,42 As 
the overall safety profile of this formulation is significantly 
better compared to other nicotinic acid formulations, it is the 
form that is now being evaluated in the ongoing outcome 
studies. In particular, the ER form does not raise particular 
concerns related to hepatotoxicity. In a 59-week-study 
which evaluated once-daily dosing ER niacin, only two 
subjects out of 723 had aspartate aminotransferase (AST) 
levels 3 times the upper limit of normal (ULN) and no 
subjects with alanine aminotransferase (ALT) 3 times 
ULN.81 Trials involving the combination of ER niacin and a Drug, Healthcare and Patient Safety 2010:2 67
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statin show neither evidence of hepatotoxicity nor signs of 
potentiating statin-induced myopathies.82–84
The other notable potential harmful effect of niacin is 
that it induces elevations of glucose in a dose-dependent 
manner. The mechanism by which this occurs is also not 
well understood, but it is thought to be related to its action 
on free fatty acids. In a study which investigated the effi-
cacy, safety, and tolerability of once-daily ER niacin for the 
treatment of dyslipidemia associated with type 2 diabetes it 
was found that at week 16 the HbA1c did show an increase. 
This change wasn’t statistically significant in the 1 g group, 
but the increase from 7.2% to 7.5% in the 1.5 g group was 
statistically and possibly clinically significant.85 Analysis of 
data from the CDP showed that regardless of how patients 
were grouped, niacin appeared as effective in lowering 
cardiovascular outcomes in patients with hyperglycemia as 
it is in patients with normoglycemia.86 The current Position 
Statement from the American Diabetes Association sug-
gests the use of nicotinic acid as an option in treating 
lipoprotein fractions other than LDL-C. It reports that 
only modest changes in glucose occur and that these are 
generally amenable to adjustment of diabetes therapy.87 
A previous statement88 discouraged its routine use, as do the 
recent UK-based National Institute of Health and Clinical 
Excellence guidelines for management of diabetes.89
Despite its having a better side-effect profile compared 
to the other forms of niacin, the discontinuation rate of the 
ER niacin still remains significant. The uncovering of the 
mechanism by which flushing is induced has sparked new 
promise into therapeutic lipid management.84,90 In general, 
flushing symptoms can occur following vasodilatation 
of small capillaries under the skin, a response that can 
be mediated via histamine/bradykinin or prostaglandins 
(PGs). This side-effect is not unique to niacin but is also 
seen with other drugs such as selective serotonin reuptake 
inhibitors.84 The flushing of niacin is not believed to be 
via histamine/bradykinin pathways, but rather via PGs. 
The G-protein-coupled receptor GRP109A, seen in 
adipocytes, also exists on dermal dendritic cells. Activation 
of the receptor on these cells induces the mobilization of 
Smooth muscle cell
Dermal 
dendritic 
cell
G1
Niacin
Arachidonic acid
PGE2 PGD2
Vasodilation and flush
DP1, EP2 EP4 
receptors 
G-protein coupled
receptor
Figure 1 Schematic illustration of the mechanism by which niacin induces flushing.
Abbreviation: PG, prostaglandin.Drug, Healthcare and Patient Safety 2010:2 68
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arachidonic acid which leads to its conversion to, amongst 
other effects, the production of vasodilatory PGs, specifically 
forms D2 and E2. These PGs cause their effects by acting 
in particular through the DP1, EP2, and EP4 receptors.84,90 
Figure 1 illustrates schematically the mechanism by which 
niacin induces flushing. Considering the advantageous 
effects of niacin, strategies to improve patient compliance 
by reducing flushing are important. This can be managed by 
various approaches namely: dose titration, patient education 
and additional pharmacological therapies.84 Nonsteroidal 
anti-inflammatory drugs are a logical treatment option as they 
are able to decrease the production of multiple prostaglandins 
by inhibiting cyclooxygenase and endoperoxidase (also 
referred to as COX).84,91
Laropiprant
Mitigation of the downstream flushing effect of niacin by 
blockade of the PG receptors is another potential treatment 
option. The discovery of a selective DP1 antagonist, MK-0542 
(also known as laropiprant), was recently described, and com-
bination of laropiprant with ER niacin has gained approval in 
Europe.92 Interestingly laropiprant was initially investigated 
as a treatment option for allergic rhinitis.92,93 Laropiprant 
is primarily metabolized by liver glucuronidation.94 Laro-
piprant has detectable off-target antagonist effects at the 
thromboxane A receptor, but no clinically significant effect 
on collagen-induced platelet aggregation, or bleeding times, 
with multiple doses up to 200 mg which is five times lower 
than the current dose regimen.95 Table 2 depicts the notable 
clinical trials of niacin/laropiprant combination in patients 
with mixed dyslipidemias and primary hypercholesterol-
emia. Laropiprant does not seem to alter the lipid-modifying 
effect of niacin or statins.96,97 In a randomized controlled 
trial which consisted of three arms: placebo, ER niacin, 
and the combination of ER niacin with laropiprant, the 
combination lowered LDL-C by 18%, triglycerides by 25% 
and increased HDL-C by 20%, which was similar to ER 
niacin only.96 This trial, along with several others,98,99 clearly 
demonstrated the attenuation of flushing with laropiprant. 
In this 24-week study the discontinuation due to flushing 
was 10% in the combination group versus 22% in the ER 
niacin group without laropiprant, compared to 0.7% in the 
placebo group.96
In April 2008, the Food and Drug Administration (FDA) 
rejected the licensing application of the laropiprant/niacin 
combination which has lead to much speculation.100 The 
FDA has however approved combinations of ER niacin with 
both simvastatin and lovastatin. Therefore the hesitancy to 
license this new combination may be related to laropiprant. 
Laropiprant is a first-in-class compound. Recently there has 
been increased skepticism and debate about surrogate mark-
ers in the field of lipids and diabetes which may have tipped 
the scales towards conservatism and a demand for outcome 
data.37 Most would regard the FDA review process as highly 
Table 2 Notable studies with niacin/laropiprant combination in patients with mixed dyslipidemias and primary hypercholesterolemia 96–98
Study Year reported  
reference
Interventions Number of patients 
study duration
Outcome  
measures
Note
Efficacy and tolerability  
of er niacin/laropiprant
2008 Reference 96 •  er niacin  
•  er niacin and Laropiprant 
•  Placebo
n = 1613 
6 months
•  Lipid parameters
•  Flushing
Discontinuation due 
to flushing:  
•  er niacin = 22% 
•    er niacin and 
  Laropiprant = 10% 
•  Placebo = 1%
er niacin/laropiprant  
and simvastatin versus  
er niacin/laropiprant  
or simvastatin
2009 Reference 97 •    er niacin and Laropiprant  
plus simvastatin
•  er niacin and Laropiprant 
•  Simvastatin
n = 1398
3 months
•  Lipid parameters % reduction LDL-C  
•    er niacin and 
Laropiprant plus 
  simvastatin = 47% 
•    er niacin and 
  Laropiprant = 17% 
•  Simvastatin = 37%
Flushing profile of ER  
niacin/laropiprant  
versus gradually  
titrated niacin er
2009 Reference 98 •  er niacin 
•  er niacin and Laropiprant
n = 1455 
4 months
•    Safety and 
tolerability
•  Flushing
Discontinuation due 
to flushing:   
•  er niacin = 12%  
•    er niacin and 
  Laropiprant = 7%
Abbreviations: er, extended release; LDL-C, low density lipoprotein cholesterol.Drug, Healthcare and Patient Safety 2010:2 69
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successful, however it is not without its limitations of gaps, 
tensions and conflicts.101
Conclusion
Niacin has a long history of success in reducing LDL-C and 
TGs and increasing HDL-C. It was the first lipid-lowering 
drug to demonstrate a reduction in CVD events, and remains 
the only one that has consistently shown benefits on surrogate 
outcomes when added to background therapies of other 
lipid-lowering drugs including statins. Despite its ability to 
significantly improve all these lipid parameters, relatively 
few clinicians resort to niacin as a treatment option. Apart 
from lacking evidence in demonstrating a benefit on all cause 
mortality and on CVD events on the background of statin 
therapy, its use has been hampered by its side-effect profile. 
The most notable side-effect of niacin is flushing. This is 
significant enough to cause discontinuation in up to 50%. 
More modern formulations of intermediate-release niacin 
show reduced side-effects but are still limited by relatively 
high discontinuation rates. The recent formulation of inter-
mediate-release niacin with a prostaglandin D2 receptor 
inhibitor (laropiprant) has become available, and provides 
a definite improvement on the side-effect profile, as well as 
patient compliance to treatment. Whether this reduced rate 
of side-effects is acceptable today is uncertain, as patients 
complain about statins which have side-effect rates which 
are still lower. The other lipid-modifying properties of niacin 
are probably advantageous; however controversy remains as 
to the direct benefits of raising HDL-C and lowering TGs. 
Given these considerations, guidelines are unlikely to change 
until the niacin-statin endpoint trials are completed. The ques-
tion as to the height of the bar for drug licensing sparks a lot 
of debate and there has been a shift which demands longer 
studies, more data and better-quality data prior to licensing.102 
The balance between causing harm, and potentially denying 
a patient useful treatment is delicate. The evaluation remains 
complex, and this requires clinical acumen.
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